Related Experiment Video
Updated: Feb 4, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Improving the bioavailability of nintedanib by formulating inhalable ufasomes as a targeted therapy for non-small
Salman M Ghazwani1, Sami Alhazmi2, Salhah M Ghazwani3
1Department of Surgery, Faculty of Medicine, Jazan University, Saudi Arabia.
Abstract:
The safety and effectiveness of nintedanib in treating non-small cell lung cancer (NSCLC) have been evaluated in several clinical trials. However, nintedanib exhibits low oral bioavailability due to its poor solubility and first-pass metabolism. To enhance the sustainability, targeting, bioavailability, and effectiveness of nintedanib, a targeted therapy for NSCLC was developed in the form of nebulized nintedanib ufasomes (NLU). Various NLU formulations were optimized utilizing the Design Expert software. The selected NLU was then evaluated for its aerodynamics, cytotoxicity, bioavailability, and targeting capabilities. To evaluate the effectiveness and safety of the optimal NLU formulation, a dose-dependent study was conducted using a mouse model of lung cancer induced by Lewis lung carcinoma (LLC) cell lines. The selected NLU formulation increased the sustainability, bioavailability, and targeting capability of nintedanib by 49.5 %, 6.63-fold, and 8.99-fold, respectively. Additionally, it decreased the IC50 value by 4.7-fold. The nebulized NLU showed better anti-tumor, anti-inflammatory, and anti-oxidative effects than oral nintedanib in terms of LDH, CEA, AFP, MDA, TNF-α, and IL-1β. The histopathological analysis confirmed these results. The safety and efficacy studies demonstrated that the nebulized NLU formulation at a dose of 100 mg/kg could serve as a viable therapy for NSCLC.
Insights
Nebulized nintedanib ufasomes (NLU) offer improved lung cancer treatment. This novel formulation enhances nintedanib
Area of Science:
- Pharmacology
- Drug Delivery Systems
- Oncology
Background:
- Nintedanib is used for non-small cell lung cancer (NSCLC).
- Nintedanib has poor oral bioavailability due to low solubility and first-pass metabolism.
- There is a need for improved drug delivery methods for nintedanib in NSCLC treatment.
Purpose of the Study:
- To develop and evaluate nebulized nintedanib ufasomes (NLU) for enhanced NSCLC therapy.
- To improve nintedanib's sustainability, targeting, bioavailability, and effectiveness.
Main Methods:
- Formulation optimization using Design Expert software.
- Evaluation of NLU aerodynamics, cytotoxicity, bioavailability, and targeting.
- In vivo efficacy and safety study in a Lewis lung carcinoma (LLC) mouse model.
Main Results:
- NLU significantly increased nintedanib's sustainability (49.5%), bioavailability (6.63-fold), and targeting (8.99-fold).
- NLU reduced the IC50 value by 4.7-fold.
- Nebulized NLU demonstrated superior anti-tumor, anti-inflammatory, and anti-oxidative effects compared to oral nintedanib.
Conclusions:
- Nebulized nintedanib ufasomes (NLU) represent a promising targeted therapy for NSCLC.
- The optimal NLU formulation at 100 mg/kg is safe and effective.
- NLU overcomes the limitations of oral nintedanib, offering enhanced therapeutic potential.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Lung Capacity
Inhaled Medications
Bioavailability: Overview
Bioavailability: Overview

